ImmunoLogic, Episode 1: "Chemo-Free Lymphoma? Seriously?" With Stephen J. Schuster, MD

Commentary
Podcast

In Episode 1 of ImmunoLogic, Stephen J. Schuster, MD, discussed the potential of treating lymphoma without chemotherapy.

Episode Breakdown

  • 0:00 – Intro and guest introduction
  • 2:47 – Discussion on chemotherapy in lymphoma treatment
  • 12:34 – Artificial intelligence in predicting lymphoma outcomes
  • 19:30 – Lymphocyte fitness and CAR T-cell therapy
  • 24:01 – Persistence and retreatment of CAR T-cells
  • 31:22 – Disease control and tumor volume

We're excited to introduce the ImmunoLogic video podcast, hosted by Joseph Fraietta, PhD, an assistant professor of microbiology and the director of the Fraietta Lab at the University of Pennsylvania! Fraietta is joined by cohost Janna Minehart, MD, a clinical fellow in oncology (MSTR Program) at the University of Pennsylvania. Our hope is that this show will become a critical forum for clinicians, translational researchers, and biotech professionals to explore the evolving landscape of immunotherapy. We're seeking to bridge cutting-edge research with practical applications and delve into how immune-based therapies transition from innovative discoveries to transformative patient care solutions

In this episode, the cohosts speak with Stephen J. Schuster, MD, the director of the Lymphoma Program at Penn Medicine, about the changing role of chemotherapy in lymphoma treatment, and the potential for its elimination. Schuster covered topics including trials for chimeric antigen receptor T-cell (CAR-T) therapy without lymphodepletion, using AI to predict CAR-T treatment outcomes, the importance of T-cell fitness, and the role of persistence in CAR-T success.

ImmunoLogic is tailored for an audience fluent in the language of medicine and biotechnology, offering data-driven insights while maintaining accessibility. This podcast is an essential resource for those driving the future of immunotherapy.

Interested in co-hosting an episode or being a guest? Have feedback to share? If you'd like to get in touch to talk about the show, contact our editorial director, Matt Hoffman: [email protected].
Recent Videos
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Related Content
CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – January 31, 2025

CGTLive Staff
January 31st 2025
Article

Review top news and interview highlights from the week ending January 31, 2025.

ImmunoLogic

CGTLive® Presents: ImmunoLogic, A Video Podcast With Joseph Fraietta, PhD

Joseph A. Fraietta, PhD;Noah Stansfield;Matt Hoffman
December 18th 2024
Podcast

Hosted by Joseph Fraietta, PhD, ImmunoLogic will be tailored for an audience fluent in the language of medicine and biotechnology, offering data-driven insights while maintaining accessibility.

uniQure Makes Progress in Trial for SOD1-ALS Gene Therapy AMT-162

uniQure Makes Progress in Trial for SOD1-ALS Gene Therapy AMT-162

Noah Stansfield
January 30th 2025
Article

The company received a recommendation from the study’s IDMC to move onto enrollment for the trial’s second cohort.

Jonathan Parker, MD, PhD, an assistant professor of neurosurgery at Mayo Clinic Arizona

The Promise of Cell Therapy Approaches in Epilepsy

Marco Meglio
December 17th 2024
Podcast

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Jonathan Parker, MD, PhD.

Sarepta’s DMD Gene Therapy Elevidys Shows Sustained Benefit in Updated Phase 3 Data

Sarepta’s DMD Gene Therapy Elevidys Shows Sustained Benefit in Updated Phase 3 Data

Noah Stansfield
January 29th 2025
Article

With regard to safety, the company stated that no new safety signals have been reported.

Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)

Evaluating Lyell’s CAR-T IMPT-314 in LBCL

Sarah Larson, MD;Noah Stansfield
January 28th 2025
Article

Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program at UCLA, discussed initial data from a phase 1/2 trial.

© 2025 MJH Life Sciences

All rights reserved.